Community-Acquired Pneumonia



In the United States, community-acquired pneumonia (CAP) in adults results in approximately 600,000 hospital admissions annually and ranks as the sixth leading cause of death. The mortality rate from CAP varies dramatically depending on the patient’s severity of illness at presentation and underlying comorbid conditions. In the outpatient setting, the mortality rate is <1–5%; however, once patients require hospitalization, the mortality rate approaches 12%. Of those patients with CAP hospitalized, between 18 and 36% require treatment in an ICU. The mortality of these patients is about 35%. While approximately 20% of patients admitted to the ICU with CAP are in septic shock, the mortality of these patients may be as high as 60%.


Chronic Obstructive Pulmonary Disease Mycoplasma Pneumoniae Eosinophilic Pneumonia Cryptogenic Organize Pneumonia Influenza Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.PubMedCrossRefGoogle Scholar
  2. 2.
    van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005;60:672–678.PubMedCrossRefGoogle Scholar
  3. 3.
    Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161:1837–1842.PubMedCrossRefGoogle Scholar
  4. 4.
    Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123:1503–1511.PubMedCrossRefGoogle Scholar
  5. 5.
    Rodriguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007;35:1493–1498.PubMedCrossRefGoogle Scholar
  6. 6.
    Lodise TP, Kwa A, Cosler L, et al. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007;51:3977–3982.PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother. 2007;60:1155–1158.PubMedCrossRefGoogle Scholar
  8. 8.
    Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophil airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148–155.PubMedCrossRefGoogle Scholar
  9. 9.
    Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis. 2002;35:819–824.PubMedCrossRefGoogle Scholar
  10. 10.
    Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2005;40:562–573.PubMedCrossRefGoogle Scholar
  11. 11.
    Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436–1444.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Pulmonary and Critical Care MedicineEastern Virginia Medical SchoolNorfolkUSA

Personalised recommendations